627
Participants
Start Date
December 11, 2014
Primary Completion Date
August 2, 2017
Study Completion Date
February 14, 2022
DTG
DTG is supplied as 50 mg tablets
LPV/RTV
LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
Two NRTIs
Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
GSK Investigational Site, Lima
GSK Investigational Site, Lima
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Rosario
GSK Investigational Site, Soweto
GSK Investigational Site, Westdene
GSK Investigational Site, Durban
GSK Investigational Site, Córdoba
GSK Investigational Site, Observatory, Cape Town
GSK Investigational Site, Bloemfontein
GSK Investigational Site, Bangkok
GSK Investigational Site, Ratchatewi
GSK Investigational Site, Nonthaburi
GSK Investigational Site, México
GSK Investigational Site, Vinnytsia
GSK Investigational Site, Khon Kaen
GSK Investigational Site, Guadalajara
GSK Investigational Site, Chiang Mai
GSK Investigational Site, Odesa
GSK Investigational Site, Zaporizhzhya
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Moscow
GSK Investigational Site, Bogotá
GSK Investigational Site, Moscow
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Shanghai
GSK Investigational Site, Smolensk
GSK Investigational Site, Krasnodar
GSK Investigational Site, Cluj-Napoca
GSK Investigational Site, Kazan'
GSK Investigational Site, Toliyatti
GSK Investigational Site, Guangzhou
GSK Investigational Site, Târgu Mureş
GSK Investigational Site, Yekaterinburg
GSK Investigational Site, Kemerovo
GSK Investigational Site, Barnaul
GSK Investigational Site, Constanța
GSK Investigational Site, Bogotá
GSK Investigational Site, Puente Alto - Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Santiago
GSK Investigational Site, Rio de Janeiro
GSK Investigational Site, Ciudad Autónoma de Buenos Aires
GSK Investigational Site, Ciudad de Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Salvador
GSK Investigational Site, São Paulo
GSK Investigational Site, São Paulo
GSK Investigational Site, Nairobi
GSK Investigational Site, Distrito Federal
GSK Investigational Site, Mexico City
GSK Investigational Site, Callao
GSK Investigational Site, Lima
GSK Investigational Site, Bucharest
GSK Investigational Site, Bucharest
GSK Investigational Site, Kyiv
Lead Sponsor
Collaborators (1)
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY